

## CTLA-4 and CD137 in cervical carcinoma

**Supplementary Table 1.** Summary of *benign* cervical tissue cores with CTLA-4 and CD137 expression, scores, and the interpretation

| No. | Age | Pathology  | CTLA4+ (%) | Intensity | Score | Expression | Interpretation | LPI     | LPI: CD137+ (%) |
|-----|-----|------------|------------|-----------|-------|------------|----------------|---------|-----------------|
| 1   | 64  | Normal     | 0          | 0         | 0     | Negative   | Negative       | Present | 0               |
| 2   | 64  | Normal     | 40         | 1+        | 1a    | LoPos      | Negative       | Present | 100             |
| 3   | 50  | Cervicitis | 0          | 0         | 0     | Negative   | Negative       | Present | 0               |
| 4   | 48  | Cervicitis | 0          | 0         | 0     | Negative   | Negative       | Present | 0               |

LPI, Lymphoplasmacytic infiltrate; LoPos, low positive interpreted as "Negative".

**Supplementary Table 2.** Subgroup IA, summary of the cores with squamous cell carcinoma (Grade I) with CTLA-4 and CD137 expression

| No. | Age | Stage  | CTLA4+ (%) | Intensity | Score | Expression | Interpretation | LPI     | LPI: CD137+ (%) |
|-----|-----|--------|------------|-----------|-------|------------|----------------|---------|-----------------|
| 1   | 44  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 2   | 37  | T1N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 0               |
| 3   | 45  | T3N0M0 | 5          | 1+        | 1a    | LoPos      | Negative       | Present | 50              |
| 4   | 68  | T1N1M0 | 80         | 1+        | 2a    | Positive   | Negative       | Present | 80              |
| 5   | 51  | T1N0M0 | 10         | 2+        | 1b    | LoPos      | Positive       | Present | 80              |
| 6   | 63  | T1N0M0 | 50         | 2+        | 2b    | Positive   | Positive       | Present | 80              |
| 7   | 46  | T1N0M0 | 80         | 2+        | 2b    | Positive   | Positive       | Present | 80              |

Positive; interpretation includes "1b", and "2b" scores; LPI, Lymphoplasmacytic infiltrate; LoPos, low positive.

**Supplementary Table 3.** Subgroup IB, summary of the cores with squamous cell carcinoma (Grade II) with CTLA-4 and CD137 expression

| No. | Age | Stage  | CTLA4+ (%) | Intensity | Score | Expression | Interpretation | LPI     | LPI: CD137+ (%) |
|-----|-----|--------|------------|-----------|-------|------------|----------------|---------|-----------------|
| 1   | 51  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 2   | 57  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 3   | 44  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 4   | 44  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 5   | 46  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 6   | 63  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 7   | 44  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 8   | 43  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 9   | 50  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 10  | 58  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 11  | 30  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 12  | 40  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 13  | 36  | T1N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 14  | 43  | T1N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 30              |
| 15  | 67  | T1N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 16  | 39  | T1N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 40              |
| 17  | 46  | T1N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 18  | 46  | T1N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 19  | 56  | T2N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 20  | 55  | T2N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 21  | 47  | T4N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 22  | 48  | T1N0M0 | 5          | 1+        | 1a    | LoPos      | Negative       | Present | 50              |
| 23  | 44  | T1N0M0 | 10         | 1+        | 1a    | LoPos      | Negative       | Present | 50              |
| 24  | 45  | T1N0M0 | 10         | 1+        | 1a    | LoPos      | Negative       | Present | 50              |

## CTLA-4 and CD137 in cervical carcinoma

|    |    |        |    |    |    |          |          |         |    |
|----|----|--------|----|----|----|----------|----------|---------|----|
| 25 | 40 | T1N0M0 | 10 | 1+ | 1a | LoPos    | Negative | Present | 50 |
| 26 | 37 | T1N1M0 | 10 | 1+ | 1a | LoPos    | Negative | Present | 50 |
| 27 | 45 | T1N0M0 | 20 | 1+ | 1a | LoPos    | Negative | Present | 80 |
| 28 | 41 | T1N1M0 | 30 | 1+ | 1a | LoPos    | Negative | Present | 80 |
| 29 | 30 | T1N0M0 | 80 | 1+ | 2a | Positive | Negative | Present | 80 |
| 30 | 54 | T1N0M0 | 80 | 1+ | 2a | Positive | Negative | Present | 50 |
| 31 | 57 | T1N0M0 | 80 | 1+ | 2a | Positive | Negative | Present | 0  |
| 32 | 37 | T1N1M0 | 80 | 1+ | 2a | Positive | Negative | Present | 90 |
| 33 | 41 | T1N1M0 | 80 | 1+ | 2a | Positive | Negative | Present | 90 |
| 34 | 47 | T2N0M0 | 80 | 1+ | 2a | Positive | Negative | Present | 80 |
| 35 | 50 | T2N0M0 | 80 | 1+ | 2a | Positive | Negative | Present | 80 |
| 36 | 49 | T2N1M0 | 80 | 1+ | 2a | Positive | Negative | Present | 50 |
| 37 | 41 | T1N0M0 | 5  | 2+ | 1b | LoPos    | Positive | Present | 80 |
| 38 | 47 | T1N0M0 | 5  | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 39 | 42 | T1N1M0 | 10 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 40 | 47 | T1N1M0 | 10 | 2+ | 1b | LoPos    | Positive | Present | 80 |
| 41 | 37 | T1N0M0 | 20 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 42 | 40 | T1N0M0 | 20 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 43 | 54 | T1N0M0 | 20 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 44 | 43 | T1N0M0 | 20 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 45 | 43 | T1N0M0 | 20 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 46 | 60 | T1N1M0 | 20 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 47 | 41 | T1N0M0 | 30 | 2+ | 1b | LoPos    | Positive | Present | 50 |
| 48 | 57 | T1N1M0 | 40 | 2+ | 1b | LoPos    | Positive | Present | 0  |
| 49 | 35 | T1N0M0 | 60 | 2+ | 2b | Positive | Positive | Present | 80 |
| 50 | 35 | T1N0M0 | 60 | 2+ | 2b | Positive | Positive | Present | 50 |
| 51 | 30 | T1N0M0 | 80 | 2+ | 2b | Positive | Positive | Present | 50 |
| 52 | 37 | T1N0M0 | 80 | 2+ | 2b | Positive | Positive | Present | 10 |

Positive, interpretation includes "1b", and "2b" scores; LPI, Lymphoplasmacytic infiltrate; LoPos, low positive.

**Supplementary Table 4.** Subgroup IC, summary of the cores with squamous cell carcinoma (Grade III) with CTLA-4 and CD137 expression

| No. | Age | Stage  | CTLA4+ (%) | Intensity | Score | Expression | Interpretation | LPI     | LPI: CD137+ (%) |
|-----|-----|--------|------------|-----------|-------|------------|----------------|---------|-----------------|
| 1   | 34  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 0               |
| 2   | 58  | T1N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 3   | 43  | T2N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 0               |
| 4   | 52  | T2N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 5   | 50  | T2N0M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 6   | 35  | T2N1M0 | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 7   | 59  | T1N1M0 | 20         | 1+        | 1a    | LoPos      | Negative       | Present | 50              |
| 8   | 39  | T1N1M0 | 40         | 1+        | 1a    | LoPos      | Negative       | Present | 0               |
| 9   | 30  | T1N0M0 | 80         | 1+        | 2a    | Positive   | Negative       | Present | 80              |
| 10  | 36  | T1N0M0 | 80         | 1+        | 2a    | Positive   | Negative       | Present | 50              |
| 11  | 45  | T2N1M0 | 80         | 1+        | 2a    | Positive   | Negative       | Present | 50              |
| 12  | 31  | T1N0M0 | 10         | 2+        | 1b    | LoPos      | Positive       | Present | 50              |
| 13  | 36  | T1N0M0 | 60         | 2+        | 2b    | Positive   | Positive       | Present | 0               |
| 14  | 33  | T2N0M0 | 60         | 2+        | 2b    | Positive   | Positive       | Present | 20              |
| 15  | 58  | T1N0M0 | 70         | 2+        | 2b    | Positive   | Positive       | Present | 50              |

Positive, interpretation includes "1b", and "2b" scores; LPI, Lymphoplasmacytic infiltrate; LoPos, low positive.

## CTLA-4 and CD137 in cervical carcinoma

**Supplementary Table 5.** Group II, summary of the cores with adenosquamous carcinoma with CTLA-4 and CD137 expression

| No. | Age | Stage  | CTLA4+ (%) | Intensity | Score | Expression | Interpretation | LPI     | LPI: CD137+ (%) |
|-----|-----|--------|------------|-----------|-------|------------|----------------|---------|-----------------|
| 1   | 27  | T2NOMO | 0          | 0         | 0     | Negative   | Negative       | Present | 50              |
| 2   | 48  | T1NOMO | 20         | 1+        | 1a    | LoPos      | Negative       | Present | 50              |
| 3   | 36  | NA     | 90         | 1+        | 2a    | Positive   | Negative       | Present | 90              |
| 4   | 36  | T1NOMO | 20         | 2+        | 1b    | LoPos      | Positive       | Present | 50              |
| 5   | 46  | T1NOMO | 20         | 2+        | 1b    | LoPos      | Positive       | Present | 90              |
| 6   | 31  | T2NOMO | 80         | 2+        | 2b    | Positive   | Positive       | Present | 50              |
| 7   | 44  | T2N1M0 | 80         | 2+        | 2b    | Positive   | Positive       | Present | 50              |
| 8   | 56  | T1NOMO | 80         | 2+        | 2b    | Positive   | Positive       | Present | 0               |

Positive, interpretation includes "1b", and "2b" scores; LPI, Lymphoplasmacytic infiltrate; LoPos, low positive; NA, not available.

**Supplementary Table 6.** Group III, summary of the cores with endocervical adenocarcinoma with CTLA-4 and CD137 expression

| No. | Age | Stage  | CTLA4+ (%) | Intensity | Score | Expression | Interpretation | LPI     | LPI: CD137+ (%) |
|-----|-----|--------|------------|-----------|-------|------------|----------------|---------|-----------------|
| 1   | 42  | NA     | 10         | 1+        | 1a    | LoPos      | Negative       | Present | 90              |
| 2   | 40  | NA     | 20         | 1+        | 1a    | LoPos      | Negative       | Present | 5               |
| 3   | 29  | NA     | 30         | 1+        | 1a    | LoPos      | Negative       | Present | 90              |
| 4   | 48  | T1NOMO | 20         | 1+        | 1a    | LoPos      | Negative       | Present | 90              |
| 5   | 33  | NA     | 30         | 2+        | 1b    | LoPos      | Positive       | Present | 90              |
| 6   | 40  | T1NOMO | 0          | 0         | 0     | Negative   | Negative       | Present | 80              |
| 7   | 48  | T1NOMO | 20         | 1+        | 1a    | LoPos      | Negative       | Present | 90              |
| 8   | 47  | T1NOMO | 30         | 1+        | 1a    | LoPos      | Negative       | Present | 80              |
| 9   | 24  | T1NOMO | 30         | 1+        | 1a    | LoPos      | Negative       | Present | 50              |
| 10  | 38  | T1NOMO | 30         | 1+        | 1a    | LoPos      | Negative       | Present | 90              |
| 11  | 50  | T1NOMO | 90         | 1+        | 2a    | Positive   | Negative       | Present | 90              |
| 12  | 39  | T1N1M0 | 90         | 1+        | 2a    | Positive   | Negative       | Present | 90              |
| 13  | 39  | T2NOMO | 80         | 2+        | 2b    | Positive   | Positive       | Present | 10              |

Positive, interpretation includes "1b", and "2b" scores; LPI, Lymphoplasmacytic infiltrate; LoPos, low positive; NA, not available.